Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity (STEP 2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03552757
Recruitment Status : Active, not recruiting
First Posted : June 12, 2018
Last Update Posted : May 10, 2019
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S

Brief Summary:
This study will look at the change in the participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the study medicine, the participant will have talks with study staff about healthy food choices, how to be more physically active and what else the participant can do to lose weight. Overweight and obesity is associated with an increased risk of type 2 diabetes. Therefore, weight loss has shown to have a beneficial impact on the blood sugar levels. The participant will either get semaglutide or "dummy" medicine - which treatment the participant get is decided by chance. The participant will need to take 2 injections at the same time once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. The study will last for about 1.5 years

Condition or disease Intervention/treatment Phase
Obesity Overweight Drug: Semaglutide 1.0 mg Drug: Semaglutide 2.4 mg Drug: Placebo I (Semaglutide) Drug: Placebo II (Semaglutide) Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1210 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity and Type 2 Diabetes
Actual Study Start Date : June 4, 2018
Estimated Primary Completion Date : March 16, 2020
Estimated Study Completion Date : May 4, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Semaglutide

Arm Intervention/treatment
Experimental: Semaglutide 1.0 mg
Participants will receive semaglutide 1.0 mg and semaglutide placebo I during 68-week treatment period in addition to a reduced-calorie diet and increased physical activity.
Drug: Semaglutide 1.0 mg
Subcutaneous (s.c.) injections of semaglutide once weekly at an escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week). The dose will be escalated to next level every 4 weeks.

Drug: Placebo I (Semaglutide)
S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide 2.4 mg (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week, 1.7 mg/week and 2.4 mg/week). The dose will be escalated to next level every 4 weeks.

Experimental: Semaglutide 2.4 mg
Participants will receive semaglutide 2.4 mg and semaglutide placebo II during 68-week treatment period in addition to a reduced-calorie diet and increased physical activity.
Drug: Semaglutide 2.4 mg
Subcutaneous injections of semaglutide once weekly at an escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week, 1.7 mg/week and 2.4 mg/week). The dose will be escalated to next level every 4 weeks.

Drug: Placebo II (Semaglutide)
S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide 1.0 mg (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week). The dose will be escalated to next level every 4 weeks.

Placebo Comparator: Semaglutide placebo I/II
Participants will receive semaglutide placebo I and II during 68-week treatment period in addition to a reduced-calorie diet and increased physical activity.
Drug: Placebo I (Semaglutide)
S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide 2.4 mg (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week, 1.7 mg/week and 2.4 mg/week). The dose will be escalated to next level every 4 weeks.

Drug: Placebo II (Semaglutide)
S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide 1.0 mg (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week). The dose will be escalated to next level every 4 weeks.




Primary Outcome Measures :
  1. Change in body weight [ Time Frame: Week 0, week 68 ]
    Measured in %

  2. Subjects who achieve (yes/no): Body weight reduction greater than or equal to 5% [ Time Frame: Week 0, week 68 ]
    Number of subjects


Secondary Outcome Measures :
  1. Subjects who achieve (yes/no): Body weight reduction greater than or equal to 10% [ Time Frame: Week 0, week 68 ]
    Number of subjects

  2. Subjects who achieve (yes/no): Body weight reduction greater than or equal to 15% [ Time Frame: Week 0, week 68 ]
    Number of subjects

  3. Change in waist circumference [ Time Frame: Week 0, week 68 ]
    Measured in centimetre

  4. Change in body weight (%) (semaglutide s.c. 2.4 mg once-weekly versus semaglutide s.c. 1.0 mg once-weekly) [ Time Frame: Week 0, week 68 ]
    Measured in %

  5. Change in haemoglobin A1c (HbA1c) [ Time Frame: Week 0, week 68 ]
    Measured in %

  6. Change in HbA1c [ Time Frame: Week 0, week 68 ]
    Measured in mmol/mol

  7. Change in systolic blood pressure [ Time Frame: Week 0, week 68 ]
    Measured in mmHg

  8. Change in physical functioning score (short form-36 [SF-36]) [ Time Frame: Week 0, week 68 ]
    Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health

  9. Change in physical function domain (5-items) score (Impact of weight on quality of Life-lite [IWQoL-Lite] for Clinical Trials [CT]) [ Time Frame: Week 0, week 68 ]
    The IWQoL-Lite for CT is a 20-item modified version of a questionnaire tool designed to assess the weight-related quality of life.

  10. Change in body weight [ Time Frame: Week 0, week 68 ]
    Measured in kg

  11. Change in body mass index (BMI) [ Time Frame: Week 0, week 68 ]
    Measured in kg/m^2

  12. Change in HbA1c (semaglutide s.c. 1.0 mg once-weekly versus semaglutide placebo I/II) [ Time Frame: Week 0, week 68 ]
    Measured in %

  13. Change in HbA1c (semaglutide s.c. 1.0 mg once-weekly versus semaglutide placebo I/II) [ Time Frame: Week 0, week 68 ]
    Measured in mmol/mol

  14. Change in fasting plasma glucose (FPG) [ Time Frame: Week 0, week 68 ]
    Measured in mg/dL

  15. Change in fasting serum insulin [ Time Frame: Week 0, week 68 ]
    Measured in mIU/L

  16. Change in diastolic blood pressure [ Time Frame: Week 0, week 68 ]
    Measured in mmHg

  17. Change in total cholesterol [ Time Frame: Week 0, week 68 ]
    Measured in mg/dL

  18. Change in high density lipoprotein (HDL) cholesterol [ Time Frame: Week 0, week 68 ]
    Measured in mg/dL

  19. Change in low density lipoprotein (LDL) cholesterol [ Time Frame: Week 0, week 68 ]
    Measured in mg/dL

  20. Change in very low density lipoprotein (VLDL) cholesterol [ Time Frame: Week 0, week 68 ]
    Measured in mg/dL

  21. Change in free fatty acids [ Time Frame: Week 0, week 68 ]
    Measured in mg/dL

  22. Change in triglycerides [ Time Frame: Week 0, week 68 ]
    Measured in mg/dL

  23. Change in high sensitivity C-Reactive Protein [ Time Frame: Week 0, week 68 ]
    Measured in mg/L

  24. Change in Plasminogen Activator Inhibitor-1 (PAI-1) Activity [ Time Frame: Week 0, week 68 ]
    Measured in AU/mL

  25. Change in SF-36 (role-physical score) [ Time Frame: Week 0, week 68 ]
    Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health

  26. Change in SF-36 (bodily pain score) [ Time Frame: Week 0, week 68 ]
    Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health

  27. Change in SF-36 (general health score) [ Time Frame: Week 0, week 68 ]
    Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health

  28. Change in SF-36 (vitality score) [ Time Frame: Week 0, week 68 ]
    Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health

  29. Change in SF-36 (social functioning score) [ Time Frame: Week 0, week 68 ]
    Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health

  30. Change in SF-36 (role-emotional score) [ Time Frame: Week 0, week 68 ]
    Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health

  31. Change in SF-36 (mental health score) [ Time Frame: Week 0, week 68 ]
    Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health

  32. Change in SF-36 (physical component summary) [ Time Frame: Week 0, week 68 ]
    Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health

  33. Change in SF-36 (mental component summary) [ Time Frame: Week 0, week 68 ]
    Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health

  34. Change in IWQoL-Lite for CT (pain/discomfort domain score) [ Time Frame: Week 0, week 68 ]
    The IWQoL-Lite for CT is a 20-item modified version of a questionnaire tool designed to assess the weight-related quality of life.

  35. Change in IWQoL-Lite for CT (psychosocial domain score) [ Time Frame: Week 0, week 68 ]
    The IWQoL-Lite for CT is a 20-item modified version of a questionnaire tool designed to assess the weight-related quality of life.

  36. Change in IWQoL-Lite for CT (total score) [ Time Frame: Week 0, week 68 ]
    The IWQoL-Lite for CT is a 20-item modified version of a questionnaire tool designed to assess the weight-related quality of life.

  37. Subjects who achieve (yes/no): Responder definition value for SF-36 physical functioning score [ Time Frame: week 0, week 68 ]
    Number of subjects

  38. Subjects who achieve (yes/no): Responder definition value for IWQoL-Lite for CT physical function domain (5-items) score [ Time Frame: Week 0, week 68 ]
    Number of subjects

  39. Subjects who achieve (yes/no): HbA1c less than 7.0% (53 mmol/mol) [ Time Frame: Week 0, week 68 ]
    Number of subjects

  40. Subjects who achieve (yes/no): HbA1c less than or equal to 6.5% (48 mmol/mol) [ Time Frame: Week 0, week 68 ]
    Number of subjects

  41. Number of treatment-emergent adverse events (TEAEs) [ Time Frame: From week 0 to week 75 ]
    Number of events

  42. Number of serious adverse events (SAEs) [ Time Frame: From week 0 to week 75 ]
    Number of events

  43. Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemia episodes [ Time Frame: From week 0 to week 75 ]
    Number of events

  44. Change in pulse [ Time Frame: Week 0, week 68 ]
    measured in beats per minute

  45. Change in amylase [ Time Frame: Week 0, week 68 ]
    measured in U/L

  46. Change in lipase [ Time Frame: Week 0, week 68 ]
    measured in U/L

  47. Change in calcitonin [ Time Frame: Week 0, week 68 ]
    measured in ng/L



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female, age greater than or equal to 18 years at the time of signing informed consent
  • Body Mass Index (BMI) greater than or equal to 27 kg/m^2 '
  • History of at least one self-reported unsuccessful dietary effort to lose body weight
  • Diagnosed with type 2 diabetes (haemoglobin A1c 7-10% (53-86 mmol/mol) (both inclusive)) 180 days or longer prior to the day of screening

Exclusion Criteria:

  • A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records
  • Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of less than 30 mL/min/1.73 m^2 (less than 60 ml/min/1.73 m^2 in subjects treated with Sodium-glucose Cotransporter 2 Inhibitors) according to chronic kidney disease (CKD)-Epidemiology Collaboration (EPI) creatinine equation as defined by Kidney Disease: Improving Global Outcomes (KDIGO) 2012 by the central laboratory at screening
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a pharmacologically pupil-dilated fundus examination performed by an ophthalmologist or an equally qualified health care provider (e.g. optometrist) within the past 90 days prior to screening or in the period between screening and randomisation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03552757


  Show 150 Study Locations
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
Layout table for investigator information
Study Director: Clinical Reporting Anchor and Disclosure (1452) Novo Nordisk A/S

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT03552757     History of Changes
Other Study ID Numbers: NN9536-4374
U1111-1200-8148 ( Other Identifier: World Health Organization (WHO) )
2017-003414-10 ( Other Identifier: European Medicines Agency (EudraCT) )
First Posted: June 12, 2018    Key Record Dates
Last Update Posted: May 10, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
URL: http://www.novonordisk-trials.com

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Obesity
Overweight
Overnutrition
Nutrition Disorders
Body Weight
Signs and Symptoms